30
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1122L |
IGF-I 30-41 acetate(82177-09-1 free base)
Insulin-like Growth Factor I (30-41) acetate |
Others | Others |
IGF-I 30-41 acetate(82177-09-1 free base) (Insulin-like Growth Factor I (30-41) acetate) 是胰岛素样生长因子 I (IGF-I) 的氨基酸 30 至 41 片段。 | |||
T6419 |
BMS-536924
HY-10262,胰岛素样生长因子-1 受体拮抗剂,BMS 536924,CS-0117 |
Apoptosis; FAK; MEK; IGF-1R; Src | Angiogenesis; Apoptosis; Cytoskeletal Signaling; MAPK; Tyrosine Kinase/Adaptors |
BMS-536924 (BMS 536924) 是一种具有口服活性,竞争性和选择性的胰岛素样生长因子受体激酶和胰岛素受体抑制剂,IC50分别为 100 nM 和 73 nM。它具有抗癌活性。 | |||
TP1121 |
IGF-I (30-41) TFA(82177-09-1,FREE)
Insulin-like Growth Factor I (30-41) (TFA) |
||
IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). | |||
T8906 |
NBI-31772
NBI31772,NBI 31772 |
IGF-1R | Tyrosine Kinase/Adaptors |
NBI-31772 (NBI 31772) 是胰岛素样生长因子-1 结合蛋白 (IGFBP, Ki = 47 nM) 的有效抑制剂。 NBI-31772 可用于 IGF 反应性疾病的研究。 | |||
T2349 |
BMS-754807
|
Trk receptor; c-Met/HGFR; IGF-1R | Tyrosine Kinase/Adaptors |
BMS754807 是一种可逆的IGF-1R 抑制剂 (IC50:1.8 nM,Ki<2 nM),也是一种可逆的IR 抑制剂 (IC50:7 nM,Ki<2 nM)。它也抑制 Met (IC50:6 nM),RON (IC50:44 nM),TrkA (IC50:7 nM),TrkB (IC50:4 nM),AurA (IC50:9 nM) 和 AurB (IC50:25 nM) 的活性。 | |||
T76810 |
Ganitumab
AMG 479 |
IGF-1R | Tyrosine Kinase/Adaptors |
Ganitumab (AMG 479) 是一种高效的1型胰岛素样生长因子受体 (IGF1R) 单克隆抗体。Ganitumab 在低浓度下识别与 IGF1R 结合,KD 值为0.22 nM,Ganitumab 对小鼠 IGF1R 与 IGF1 和 IGF2 的相互作用有抑制作用。Ganitumab 可用于研究癌症。 | |||
T6017 |
Linsitinib
OSI-906,林西替尼 |
IGF-1R | Tyrosine Kinase/Adaptors |
Linsitinib (OSI-906) 是选择性的、有效的、具有口服活性的IGF-1和胰岛素受体(IR)的双重抑制剂,IC50分别为 35 和 75 nM。 | |||
T68405 |
KW-2450 free base
|
IGF-1R | Tyrosine Kinase/Adaptors |
KW-2450 free base 是一种 IGF-1R/IR和酪氨酸激酶多重抑制剂 具有抗肿瘤活性。KW-2450 free base 在小鼠 HT-29/GFP 结肠癌异种移植模型中显示出适度的生长抑制活性并抑制 IGF-1 诱导的信号转导。 | |||
T25123 |
AZ12253801
AZ 12253801,AZ-12253801 |
||
AZ12253801 is a type 1 insulin-like growth factor receptor (IGF-1R) inhibitor. | |||
T70568 |
H-1356
|
||
H-1356 is an insulin-like growth factor 1(IGF-I) analog that inhibits autophosphorylation of IGF-I receptor. | |||
T24106 |
GSK2163632A
GSK-2163632-A,GSK 2163632 A |
||
GSK2163632A is an insulin-like growth factor 1 receptor inhibitor that acts by binding to a novel region of the GRK active site cleft. | |||
T25110 |
AS1069562
AS-1069562,AS 1069562 |
||
AS1069562 is an inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake which acts by notably restoring reduced insulin-like growth factor 1 and fibroblast growth factor 2 mRNA levels in dorsal root ganglion and spinal cord, respectively. | |||
T80871 |
Veligrotug
|
IGF-1R | Tyrosine Kinase/Adaptors |
Veligrotug为IgG1-kappa型抗IGF1R(胰岛素样生长因子1受体,CD221)嵌合单克隆抗体。 | |||
T30538 |
BMS-695735
CHEMBL459729,DNC008930,BMS 695735,BMS695735,BDBM27888 |
||
BMS-695735, a benzimidazole inhibitor of insulin-like growth factor-1 receptor, has broad-spectrum antitumor activity in vivo. It was found that BMS-695735 had strong inhibition of CYP3A4, induction of CYP3A4 mediated by PXR transactivation, poor water so | |||
T76539 |
Insulin-like growth factor II
|
||
Insulin-like growth factor II (IGF-2)为人血清中主要生长激素,对神经突生长具有许可性和直接作用,同时增强交感与感觉神经元的生存能力。 | |||
T38502 |
IGF-1R inhibitor-2
|
||
IGF-1R inhibitor-2 (example 121) is a compound that inhibits the insulin-like growth factor-1 receptor (IGF-1R). By downregulating the IGF-1R, it has the potential to reverse the transformed phenotype of tumor cells and make them more susceptible to apoptosis. | |||
T61506 | NBI-31772 hydrate | ||
NBI-31772 hydrate is a powerful inhibitor of the interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). It acts as a nonpeptide ligand, effectively releasing bioactive IGF-I from the IGF-I/IGFBP-3 complex (Ki values for all six human subtypes range from 1-24 nM). This compound demonstrates significant anxiolytic and antidepressant-like effects [1] [2] [3]. | |||
T75157L |
Cimdelirsen sodium
|
||
Cimdelirsen (sodium) 为针对肝脏的反义寡核苷酸,通过减少生长激素受体(GHr)合成,抑制生长激素(GH)的过度分泌效应,进而降低肢端肥大症患者体内循环胰岛素样生长因子-1 (IGF-1)水平。 | |||
T76043L |
S961 acetate
|
||
S961 acetate 是一种高亲和力的胰岛素受体 (insulin receptor, IR) 拮抗剂,对 HIR-A,HIR-B 和人胰岛素样生长因子 I 受体 (HIGF-IR) 的 IC50分别为 0.048,0.027 和 630 nM。 | |||
T38584 |
ALK-IN-12
|
||
ALK-IN-12 is a highly potent and orally active inhibitor of anaplastic lymphoma kinase (ALK), demonstrating an exceptional IC50 value of 0.18 nM. Additionally, ALK-IN-12 displays inhibitory activity against insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (InsR), with IC50 values of 20.3 nM and 90.6 nM, respectively. Notably, its antitumor effects have been observed, making it a promising compound for targeted cancer therapy. | |||
T76043 |
S961 TFA
|
||
S961 TFA为一种与胰岛素受体(insulin receptor, IR)高亲和力相结合的拮抗剂,其IC50值对HIR-A、HIR-B及人胰岛素样生长因子I受体(HIGF-IR)分别为0.048、0.027及630 nM。 | |||
T76759 | Robatumumab | ||
Robatumumab (Sch 717454) 为针对人胰岛素样生长因子 1 受体(anti-humanIGF-1R)的抗体,展现出抗肿瘤及阻止癌细胞增殖的作用,适用于骨肉瘤与尤文肉瘤的研究。 | |||
T73702 |
Mecasermin
|
||
Mecasermin(Human IGF-I; FK 780),一种重组人胰岛素样生长因子I(IGF-I),主要用于研究因生长激素(GH)受体缺陷或GH抑制抗体导致的GH不敏感性而引起的生长障碍。 | |||
T76746 | Figitumumab | ||
Figitumumab (CP-751871) 为一种高效对抗胰岛素样生长因子 1 受体 (IGF1R) 的全人单克隆抗体。通过阻断 IGF1 与 IGF1R 的结合,其 IC50 值达到 1.8 nM。 | |||
T75157 |
Cimdelirsen
|
||
Cimdelirsen为针对肝脏的反义寡核苷酸,通过降低生长激素受体(GHr)的合成量,来减少生长激素(GH)过量分泌所导致的不良影响,进而在肢端肥大症患者中降低循环胰岛素样生长因子-1(IGF-1)的水平。 | |||
T70876 |
KW-2450 Tosylate
|
||
KW-2450 Tosylate is an orally bioavailable inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases with potential antineoplastic activity. IGF-1R/IR inhibitor KW-2450 Tosylate selectively binds to and inhibits the activities of IGF-1R and IR, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-R1 and IR tyrosine kinases, overexpressed in a variety of human cancers, play significant roles in t... | |||
T76012 |
IGF-I (30-41) (TFA)
|
||
IGF-I (30-41) (TFA) 是类胰岛素生长因子I 30 至 41 的氨基酸片段。IGF-I 对生长激素的活性有着重要的作用,但是IGF-I 本身也具有一些自身的特性,如合成代谢、抗氧化、抗炎和细胞保护作用。 | |||
T76014 |
IGF-I (24-41) (TFA)
|
||
IGF-I (24-41) TFA(Insulin-like Growth Factor I (24-41) TFA)是类胰岛素生长因子I的一个氨基酸片段,覆盖24至41位点。作为一种70个氨基酸组成的多肽激素,IGF-I TFA对神经元和神经胶质细胞具有营养作用,而且在调节全身生长激素(GH)活性中扮演关键角色。它还具备合成代谢、抗氧化、抗炎及细胞保护功能,对躯体生长及行为发育调节作用显著。 | |||
T76042 |
Angiopeptin TFA
|
||
Angiopeptin TFA,一种生长抑素的环状八肽类似物,作为sst2/sst5受体部分激动剂,其IC50值为0.26 nM和6.92 nM。该化合物能够抑制生长激素释放及IGF-1(胰岛素样生长因子-1)的产生,同时抑制腺苷酸环化酶活性或刺激细胞外酸化。Angiopeptin TFA在冠状动脉粥样硬化的研究中显示出潜力。 | |||
T83825 |
Trofinetide acetate
NNZ-2566 |
||
Trofinetide是一种衍生自具有神经保护作用的三肽Gly-Pro-Glu的化合物,后者是胰岛素样生长因子-1(IGF-1)的N-端序列。在10 nM的浓度下使用时,它能减少由蛋白磷酸酶抑制剂奥卡达酸在原代大鼠胚胎纹状体神经元中引起的细胞死亡。Trofinetide在一种由穿透性弹道样脑损伤引起的大鼠神经炎症模型中减少了编码IL-1β、TNF-α、IL-6和E-selectin的mRNA的脑表达。在通过中脑动脉闭塞(MCAO)引起的大鼠脑损伤模型中,以30和60 mg/kg的剂量给药时,它减少了皮层和纹状体梗塞区域。Trofinetide(每天100 mg/kg)减少了树突棘的数量,并逆转了在fmr1-/-敲除小鼠脆性X综合征模型中的社交识别和情景恐惧条件反射的缺陷,同时也减少了睾丸重量的增加。含有Trofinetide的制剂已被用于治疗Rett综合征。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3S0027 |
Picropodophyllotoxin
AXL 1717,Picropodophyllin,苦鬼臼毒素 |
IGF-1R | Tyrosine Kinase/Adaptors |
Picropodophyllotoxin (AXL 1717) 是一种环木脂素生物碱,存在于五月树(Podophyllum peltatum) 中,是一种具有潜在抗肿瘤活性的胰岛素样生长因子 1 受体 (IGF1R) 的小分子抑制剂。它特异性抑制 IGF1R 的活性并下调细胞表达,而不干扰其他生长因子受体的活性,例如胰岛素受体、表皮生长因子、血小板衍生生长因子、成纤维细胞生长因子和肥大/干细胞生长因子 (KIT) )。该药剂在抑制肿瘤细胞增殖和诱导肿瘤细胞凋亡方面显示出有效的活性。 IGF1R 是一种在多种人类癌症中过度表达的受体酪氨酸激酶,在多种癌细胞的生长和存活中起关键作用。 |